Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | Director | May 28, 2026 | May 29, 2026 |
| bluebird bio, Inc.BLUE · Entity 78923 | Chief Strategy Officer | August 20, 2019 | August 21, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tenaya Therapeutics, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2036-05-27 | Direct | 120,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 120,000 · Balance 120,000 F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.
bluebird bio, Inc.
Report date August 20, 2019 · Filed August 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,921 |
Ending reported balance
After 2019-08-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-08-20 · Exercise / conversion · Acquired 500 · Balance 41,421 Row 2 · 2019-08-20 · Sale · Disposed 500 · Balance 40,921 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 16, 2019. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.47 · Expires 2024-03-03 | Direct | 9,521 |
Reported balance
After 2019-08-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-08-20 · Exercise / conversion · Disposed 500 · Balance 9,521 F2: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 16, 2019.
F2: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed May 29, 2026 23:29 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 120,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001193125-26-249132 · ownership.xml · derivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2036-05-27 F1 · derivative.exercise_date: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| May 29, 2025 Filed May 30, 2025 22:53 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 107,400 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000950170-25-079949 · ownership.xml · derivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,400 Underlying: Common Stock · 107,400 shares Expires 2035-05-28 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 00:43 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 34,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0000950170-24-116065 · ownership.xml · derivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2034-10-17 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 31, 2025, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 00:41 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 29,532 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-23-036527 · doc4.xml · derivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,532 Underlying: Common Stock · 29,532 shares Expires 2033-06-08 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 01:02 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 39,727 | $0.00 Strike: $5.26 | $0.00 |
DisclosureSEC source: 0001209191-22-036543 · doc4.xml · derivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,727 Underlying: Common Stock · 39,727 shares Expires 2032-06-09 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $24.47 | $0.00 |
DisclosureSEC source: 0001209191-19-046968 · doc4.xml · derivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,521 Underlying: Common Stock · 500 shares Expires 2024-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 500 | $124.00 | $62,000.00 |
DisclosureSEC source: 0001209191-19-046968 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,921 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 16, 2019. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 500 | $24.47 | $12,235.00 |
DisclosureSEC source: 0001209191-19-046968 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 16:52 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 100 | $0.00 Strike: $24.47 | $0.00 |
DisclosureSEC source: 0001209191-19-038250 · doc4.xml · derivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,021 Underlying: Common Stock · 100 shares Expires 2024-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 16:52 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 100 | $126.12 | $12,612.00 |
DisclosureSEC source: 0001209191-19-038250 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,921 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 16:52 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 100 | $24.47 | $2,447.00 |
DisclosureSEC source: 0001209191-19-038250 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 1,400 | $0.00 Strike: $24.47 | $0.00 |
DisclosureSEC source: 0001209191-19-036381 · doc4.xml · derivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,121 Underlying: Common Stock · 1,400 shares Expires 2024-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 200 | $126.96 | $25,392.00 |
DisclosureSEC source: 0001209191-19-036381 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,921 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,200 | $125.19 | $150,227.04 |
DisclosureSEC source: 0001209191-19-036381 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,121 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F2 · price: The range of prices for the transaction reported on this line was $125.00 to $125.55. The average weighted price was $125.1892. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 16:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 1,400 | $24.47 | $34,258.00 |
DisclosureSEC source: 0001209191-19-036381 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2019 Filed May 14, 2019 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $24.47 | $0.00 |
DisclosureSEC source: 0001209191-19-029597 · doc4.xml · derivative · entry 5 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,521 Underlying: Common Stock · 1,500 shares Expires 2024-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. Read SEC document |
| May 10, 2019 Filed May 14, 2019 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 200 | $133.08 | $26,616.00 |
DisclosureSEC source: 0001209191-19-029597 · doc4.xml · nonDerivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,921 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F4 · price: The range of prices for the transaction reported on this line was $133.00 to $133.16. The average weighted price was $133.08. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2019 Filed May 14, 2019 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,100 | $132.38 | $145,613.05 |
DisclosureSEC source: 0001209191-19-029597 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,121 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F3 · price: The range of prices for the transaction reported on this line was $131.84 to $132.68. The average weighted price was $132.3755. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2019 Filed May 14, 2019 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 200 | $131.11 | $26,221.00 |
DisclosureSEC source: 0001209191-19-029597 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,221 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F2 · price: The range of prices for the transaction reported on this line was $130.61 to $131.60. The average weighted price was $131.105. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2019 Filed May 14, 2019 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 1,500 | $24.47 | $36,705.00 |
DisclosureSEC source: 0001209191-19-029597 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 16:17 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $24.47 | $0.00 |
DisclosureSEC source: 0001209191-19-024478 · doc4.xml · derivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,021 Underlying: Common Stock · 1,500 shares Expires 2024-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 16:17 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 400 | $157.23 | $62,891.00 |
DisclosureSEC source: 0001209191-19-024478 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,921 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F3 · price: The range of prices for the transaction reported on this line was $157.09 to $157.38. The average weighted price was $157.2275. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 16:17 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,100 | $156.44 | $172,084.99 |
DisclosureSEC source: 0001209191-19-024478 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,321 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F2 · price: The range of prices for the transaction reported on this line was $156.09 to $156.62. The average weighted price was $156.4409. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 16:17 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 1,500 | $24.47 | $36,705.00 |
DisclosureSEC source: 0001209191-19-024478 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 16:14 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $24.47 | $0.00 |
DisclosureSEC source: 0001209191-19-019141 · doc4.xml · derivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,521 Underlying: Common Stock · 1,500 shares Expires 2024-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 16:14 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,500 | $139.80 | $209,698.20 |
DisclosureSEC source: 0001209191-19-019141 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,921 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F2 · price: The range of prices for the transaction reported on this line was $139.30 to $140.05. The average weighted price was $139.7988. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 16:14 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 1,500 | $24.47 | $36,705.00 |
DisclosureSEC source: 0001209191-19-019141 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 16:11 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $24.47 | $0.00 |
DisclosureSEC source: 0001209191-19-009284 · doc4.xml · derivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial and · Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,021 Underlying: Common Stock · 1,500 shares Expires 2024-03-03 F4 · derivative.exercise_date: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 16:11 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 500 | $131.87 | $65,933.00 |
DisclosureSEC source: 0001209191-19-009284 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial and · Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,921 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F3 · price: The range of prices for the transaction reported on this line was $131.74 to $131.96. The average weighted price was $131.866. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 16:11 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,000 | $130.99 | $130,994.80 |
DisclosureSEC source: 0001209191-19-009284 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial and · Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,421 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F2 · price: The range of prices for the transaction reported on this line was $130.60 to $131.50. The average weighted price was $130.9948. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 16:11 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 1,500 | $24.47 | $36,705.00 |
DisclosureSEC source: 0001209191-19-009284 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial and · Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:51 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 33,750 | $0.00 Strike: $134.63 | $0.00 |
DisclosureSEC source: 0001209191-19-007459 · doc4.xml · derivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 33,750 shares Expires 2029-02-01 F2 · derivative.exercise_date: This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2020 and in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 17:51 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 8,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-007459 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,921 F1 · security: Restricted stock units for common stock vest over a four-year period at a rate of 25% on 01/04/2020, 25% on 01/04/2021, 25% on 01/04/2022, and 25% on 01/04/2023. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $24.47 | $0.00 |
DisclosureSEC source: 0001209191-19-004541 · doc4.xml · derivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,521 Underlying: Common Stock · 3,000 shares Expires 2024-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 3,000 | $125.14 | $375,428.10 |
DisclosureSEC source: 0001209191-19-004541 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,483 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F2 · price: The range of prices for the transaction reported on this line was $125.00 to $125.45. The average weighted price was $125.1427. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 3,000 | $24.47 | $73,410.00 |
DisclosureSEC source: 0001209191-19-004541 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 17:05 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,033 | $114.31 | $118,077.68 |
DisclosureSEC source: 0001209191-19-003092 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,483 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range of prices for the transaction reported on this line was $113.78 to $114.72. The average weighted price was $114.3056. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 17:05 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,979 | $113.29 | $224,198.14 |
DisclosureSEC source: 0001209191-19-003092 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,516 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range of prices for the transaction reported on this line was $112.73 to $113.70. The average weighted price was $113.2886. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 09, 2018 Filed Nov 14, 2018 16:10 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $24.47 | $0.00 |
DisclosureSEC source: 0001209191-18-058508 · doc4.xml · derivative · entry 5 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,521 Underlying: Common Stock · 1,500 shares Expires 2024-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. Read SEC document |
| November 09, 2018 Filed Nov 14, 2018 16:10 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 480 | $131.55 | $63,142.32 |
DisclosureSEC source: 0001209191-18-058508 · doc4.xml · nonDerivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,495 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F4 · price: The range of prices for the transaction reported on this line was $131.46 to $131.625. The average weighted price was $131.5465. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 09, 2018 Filed Nov 14, 2018 16:10 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 700 | $130.61 | $91,429.03 |
DisclosureSEC source: 0001209191-18-058508 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,975 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F3 · price: The range of prices for the transaction reported on this line was $130.10 to $131.06. The average weighted price was $130.6129. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 09, 2018 Filed Nov 14, 2018 16:10 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 320 | $129.12 | $41,319.20 |
DisclosureSEC source: 0001209191-18-058508 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,675 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F2 · price: The range of prices for the transaction reported on this line was $128.90 to $129.61. The average weighted price was $129.1225. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 09, 2018 Filed Nov 14, 2018 16:10 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 1,500 | $24.47 | $36,705.00 |
DisclosureSEC source: 0001209191-18-058508 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 16:53 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $24.47 | $0.00 |
DisclosureSEC source: 0001209191-18-054899 · doc4.xml · derivative · entry 5 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,021 Underlying: Common Stock · 1,500 shares Expires 2024-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 16:53 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 100 | $136.83 | $13,683.00 |
DisclosureSEC source: 0001209191-18-054899 · doc4.xml · nonDerivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,495 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 16:53 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 300 | $135.70 | $40,709.01 |
DisclosureSEC source: 0001209191-18-054899 · doc4.xml · nonDerivative · entry 3 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,595 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F3 · price: The range of prices for the transaction reported on this line was $135.55 to $135.99. The average weighted price was $135.6967. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 16:53 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,100 | $134.95 | $148,446.98 |
DisclosureSEC source: 0001209191-18-054899 · doc4.xml · nonDerivative · entry 2 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,895 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F2 · price: The range of prices for the transaction reported on this line was $134.50 to $135.33. The average weighted price was $134.9518. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 16:53 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 1,500 | $24.47 | $36,705.00 |
DisclosureSEC source: 0001209191-18-054899 · doc4.xml · nonDerivative · entry 1 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 16:12 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $24.47 | $0.00 |
DisclosureSEC source: 0001209191-18-050632 · doc4.xml · derivative · entry 5 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,521 Underlying: Common Stock · 1,500 shares Expires 2024-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 16:12 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 299 | $151.57 | $45,318.44 |
DisclosureSEC source: 0001209191-18-050632 · doc4.xml · nonDerivative · entry 4 Walsh Jeffrey T. · CIK 0001578251 · Chief Financial · and Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,495 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018. F4 · price: The range of prices for the transaction reported on this line was $151.45 to $151.70. The average weighted price was $151.5667. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.